The view
Coherent closed at $218.15 on 13 November 2026, with the share price up +39.2% over the past year yet sitting −26.5% from its 200-day average, so much of that gain has been given back. The Intrinsic Value model puts the stock at $40.73 per share, a gap of −81.3% to the price, meaning the price stands far above the model's intrinsic value. The market regime reads strong risk-off. The published 21-session view is essentially flat at +0.81%, with a probability of a rise of 42%. The published 63-session view leans up at +6.39%.
Next month: why the model view is positive
The 21-session view leans up only nominally. The expected return of +0.81% is close to zero, and the probability of a rise of 42% sits below even odds, so the reading is closer to neutral than to a firm lean. The measured facts on the cautious side are strong. Volatility sits near the top of large US stocks, strength against its sector is among the weakest, and close-to-close acceleration is the lowest in five years. The band from −40.3% to +41.9% is very wide. Across 200 past situations like today's, the median return over the next 21 sessions was +9.7%, with 69% rising. That history is more constructive than the model, and it is history, not a forecast.
Next 3 months: model view positive
The 63-session view leans up more clearly at +6.39%, with a band from −54% to +66.8%. Both views point the same way, but the shorter one is nearly flat at +0.81% while the longer one carries a visible lean. That can happen when near-term price weakness and high volatility dominate the short horizon, while slower measures weigh more over three months. Here, the growth composite, profitability and earnings quality all stand at the highest of the company's last five years. Past situations like today's rose a median +19.2% over the next 63 sessions, with 70% higher. That history agrees with the lean, though it reflects past cases under the strong risk-off backdrop only loosely.
The long term
The long-term case is the hardest to reconcile. Intrinsic value of $40.73 sits −81.3% from the price, and the price-to-earnings multiple of 59.22 ranks at percentile 86 in the sector, with price-to-book at 5.00. Return on equity is a moderate 11.2%. Debt to equity is a modest 0.34, at percentile 26 in the sector. The Piotroski score of 3 points to weak health signals despite revenue growth of +49.9%. Past situations like today's rose a median +51.4% over the following year, with 69% higher. That history and the strong growth support the longer horizons, while the valuation gap and weak financial-health score argue against them.
How sure we are
On this name, 80% of 283 matured 21-session forecasts matched the direction of the outcome, well above the base rate of about half across all names. That record is substantial. The historical comparison rests on 200 past situations matched on seven measures, not on the full set of 588 features computed today. The bands are very wide, from −40.3% to +41.9% at the shorter horizon and from −54% to +66.8% at the longer one. Any single reading here is therefore uncertain, and the near-flat 21-session expectation deserves little directional weight.